Author

H. van Panhuis

Utrecht University

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Molecular Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Annelotte M. VonkiD· 1 shared Antoni R. BlaazeriD· 1 shared Cornelis Korstiaan van der EntiD· 1 shared Edward DompelingiD· 1 shared Els J.M. WeersinkiD· 1 shared Evelien Kruisselbrink· 1 shared Eyleen de Poel· 1 shared Georgia N. Ithakisiou· 1 shared

Activity by Year

2023-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMolecular Biology

Annelotte M. VonkORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

FDA-Approved Drug Screening in Patient-Derived Organoids Demonstrates Potential of Drug Repurposing for Rare Cystic Fibrosis Genotypes

Eyleen de Poel, Sacha Spelier, Marne C. Hagemeijer, Peter van Mourik, Sylvia W.F. Suen, Annelotte M. Vonk, Jesse E. Brunsveld, Georgia N. Ithakisiou, Evelien Kruisselbrink, Hugo Oppelaar, Gitte Berkers, Karin M. de Winter‐de Groot, Sabine Heida-Michel, S.R. Jans, H. van Panhuis, , Jeffrey Matthijn Beekman

The paper screens 1400 FDA-approved drugs in CF patient-derived intestinal organoids using a functional assay to identify potential repurposing for rare CF genotypes.

Journal of Cystic Fibrosis · May 1, 2023Peer-reviewedMolecular Biology